PDGF-AA protein: The "Architect" of the Cellular World, Its Central Role in Repair, Fibrosis, and Tumors

PDGF-AA is a unique homodimeric member of the platelet-derived growth factor family, renowned for its high specificity and affinity for the PDGFR-α receptor. As a potent mitogen and chemokine, it plays a central role in embryonic development, tissue repair, and vascular homeostasis. However, its persistent activation is also a key driver of organ fibrosis, atherosclerosis, and the development of various tumors. This article will provide an in-depth analysis of the molecular characteristics and signaling mechanisms of PDGF-AA, comprehensively explore its pathological roles in fibrotic diseases, neurological disorders, cardiovascular diseases, and various cancers, and elucidate its clinical translational prospects as a diagnostic marker and therapeutic target.

I. PDGF-AA: A Precise "Cellular Mobilization and Proliferation Command"

The PDGF family consists of various subtypes (AA, BB, AB, CC, DD), which exert their effects by binding to two tyrosine kinase receptors. PDGF-AA stands out for its precise receptor selectivity, primarily binding to the PDGFR-αα homodimer, thereby defining its unique functional profile and tissue distribution.

1. Molecular Characteristics and Signal Transduction

Structural Features: Composed of two identical A chains linked by disulfide bonds.
Receptor Specificity: Primarily binds to PDGFR-α, with very low affinity for PDGFR-β. This specificity restricts its signaling to cell populations expressing PDGFR-α, such as certain glial cells, fibroblasts, smooth muscle cells, and mesenchymal stem cells.
Core Signaling Pathways: Upon receptor binding, it activates downstream RAS-MAPK, PI3K-AKT, and JAK-STAT pathways, transmitting critical commands for "proliferation," "migration," "survival," and "secretion."

2. Core Physiological Functions

• Embryonic Development: Involved in neural crest cell migration, craniofacial skeletal formation, and vascular development.
• Tissue Repair: Released by platelets and macrophages during the proliferative phase of wound healing, it strongly recruits and stimulates fibroblasts and smooth muscle cells, promoting granulation tissue formation and matrix deposition.
• Nervous System Homeostasis: A key support factor for the survival, proliferation, and differentiation of oligodendrocyte precursor cells into mature oligodendrocytes, essential for the formation and maintenance of central nervous system myelin.

II. Dysregulated PDGF-AA Signaling and Its Profound Association with Major Diseases

When PDGF-AA expression becomes uncontrolled or its signaling pathway is abnormally activated, it transforms from a "repairer" to a "destroyer."

1. Fibrotic Diseases: A Runaway "Repair Program"
PDGF-AA is recognized as one of the core cytokines driving organ fibrosis. Under chronic injury conditions, its sustained high expression leads to excessive and dysregulated repair processes.

Idiopathic Pulmonary Fibrosis:
Pathogenic Mechanism: Activated alveolar epithelial cells and inflammatory cells continuously secrete PDGF-AA, driving abnormal proliferation, migration, and excessive collagen synthesis by lung fibroblasts and myofibroblasts, resulting in irreversible lung tissue scarring (honeycomb lung).

Liver Fibrosis/Cirrhosis:
Pathogenic Mechanism: In chronic liver injury, PDGF-AA is one of the most potent factors activating hepatic stellate cells to transform into collagen-secreting myofibroblasts, directly promoting the formation of intrahepatic fibrous septa.

Renal Interstitial Fibrosis:
Pathogenic Mechanism: Promotes the activation of renal interstitial fibroblasts, participating in the common pathway of progression from various chronic kidney diseases to end-stage renal failure.

Systemic Sclerosis (Scleroderma):
Skin and Visceral Fibrosis: Elevated PDGF-AA levels in the serum and affected skin of patients, along with sustained activation of its signaling pathway, are key mediators of skin thickening and hardening, as well as fibrosis of internal organs like the lungs and digestive tract.

2. Neurological Disorders

Multiple Sclerosis:
Dual Role: On one hand, PDGF-AA is essential for remyelination, promoting the recruitment and differentiation of oligodendrocyte precursor cells to injury sites. On the other hand, excessive PDGF-AA in chronic active lesions may exacerbate inflammation and glial scar formation by activating astrocytes, hindering repair.

Glioma:
Autocrine Drive: High-grade gliomas (e.g., glioblastoma) often co-express PDGF-AA and its receptor PDGFR-α, forming a powerful autocrine growth stimulation loop that drives uncontrolled tumor cell proliferation, survival, and invasion.

3. Cardiovascular Diseases

Atherosclerosis:
Plaque Development and Instability: In arterial plaques, activated platelets, endothelial cells, and macrophages release PDGF-AA, strongly stimulating vascular smooth muscle cells to migrate from the media to the intima, proliferate, and adopt a synthetic phenotype. This leads to intimal thickening and fibrous cap formation, but excessive smooth muscle cell proliferation also contributes to lipid core formation and increased plaque instability.

Vascular Restenosis:
Post-Interventional Complication: After percutaneous coronary interventions (e.g., stent placement), PDGF-AA expression surges at vascular injury sites, becoming a core molecule driving excessive smooth muscle cell proliferation and intimal hyperplasia, leading to in-stent restenosis.

4. Tumors
Beyond gliomas, aberrant PDGF-AA signaling is closely associated with other tumors:

Gastrointestinal Stromal Tumors (GIST): Some GISTs harbor activating mutations in the PDGFR-α gene, causing ligand-independent receptor activation and serving as a driver of tumorigenesis. Tyrosine kinase inhibitors targeting this mutation (e.g., imatinib) are standard therapy.

Tumor Stroma Remodeling: Many epithelial-derived solid tumors (e.g., breast, ovarian, prostate cancer) secrete PDGF-AA to activate and recruit cancer-associated fibroblasts (CAFs). These CAFs remodel the tumor microenvironment, promoting immune suppression, angiogenesis, and tumor invasion/metastasis.

III. Clinical Prospects: From Diagnostic Markers to Targeted Therapies

In-depth understanding of the PDGF-AA pathway has given rise to two main clinical strategies.

1. As a Biomarker of Disease Activity

• Fibrotic Diseases: Measuring PDGF-AA levels in serum or bronchoalveolar lavage fluid can serve as a potential indicator for assessing disease activity and prognosis in pulmonary fibrosis.
• Tumors: The expression level of PDGFR-α or PDGF-AA concentration in tumor tissue may correlate with the malignancy and prognosis of specific cancers.

2. As a Therapeutic Target (Signal Inhibition)
Blocking the overactive PDGF-AA/PDGFR-α axis is a core strategy for treating fibrosis and related tumors.

• Small-Molecule Tyrosine Kinase Inhibitors: Drugs like imatinib, sunitinib, and nilotinib effectively inhibit PDGFR-α activity. Initially approved for chronic myeloid leukemia, imatinib later became a key treatment for PDGFR-α-mutant GIST and certain types of chronic eosinophilic leukemia due to its PDGFR-α inhibition. In clinical trials for idiopathic pulmonary fibrosis and other fibrotic diseases, these drugs have shown some antifibrotic potential, though efficacy and safety remain under investigation.
• Neutralizing Antibodies: Developing monoclonal antibodies targeting PDGF-AA or PDGFR-α for more precise blockade is an emerging research direction.

3. As a Therapeutic Tool (Local Application)
Promoting Tissue Repair: In bone tissue engineering and chronic non-healing wounds (e.g., diabetic foot ulcers), recombinant human PDGF-BB (becaplermin) has been approved as a topical gel to accelerate healing by promoting fibroblast and vascular growth. Although direct application of PDGF-AA is less studied, its potential in specific tissue (e.g., neural) repair warrants exploration.

IV. Challenges and Future Perspectives

• Precision in Therapeutic Window: The intertwined roles of PDGF-AA in physiological repair and pathological destruction mean that complete inhibition may impair normal wound healing and neural repair. Future therapies must strike a precise balance between suppressing pathological activation and preserving physiological function.
• Tissue-Specific Delivery: Developing carrier systems that can deliver inhibitors (e.g., TKIs) or recombinant proteins precisely to diseased tissues (e.g., fibrotic lungs or liver) to maximize efficacy and minimize systemic side effects.
• Combination Therapy Strategies: Given the complexity of fibrotic and tumor microenvironments, combining PDGFR inhibitors with anti-inflammatory drugs, other antifibrotic agents (e.g., anti-TGF-β), antiangiogenic drugs, or immune checkpoint inhibitors may prove more effective.

Conclusion

The PDGF-AA protein, with its specific command over PDGFR-α, plays a complex role in life processes, ranging from builder to potential destroyer. It is the "chief engineer" directing fibroblasts to repair injuries, yet also the culprit driving organs to harden into stone-like fibrous tissue; it is a vital support for maintaining healthy nervous system myelin, yet may also become the autocrine engine fueling malignant gliomas.

From the success of imatinib in GIST treatment to ongoing explorations against pulmonary fibrosis, efforts to target the PDGF-AA signaling pathway epitomize modern medicine's attempt to harness this powerful cytokine. In the future, through more precise regulation, smarter drug delivery, and rational combination strategies, we may transform this "double-edged sword" into a potent weapon against fibrotic diseases, improved cancer treatments, and tissue regeneration, offering new hope to countless patients.